Search

William D Huse

from Lees Summit, MO
Deceased
Get Report
Also known as:
William Etal Huse, Julia M A Huse, William D House, William D Anderson
Related to:
Bernadette Anderson, 67Elizabeth Anderson, 62Megan Huse, 34Frances A AndersonMichael AndersonWilliam AndersonMegan E Huse, 38Danny AndersonJulia Huse
Connected to:
Beth M Huse, 58Brooks P Huse, 40Dan C Huse, 55Eric A Huse, 37Helen K Huse, 93Jennie J Huse, 70Jon Huse, 43Judy L Huse, 71Martha A Huse, 83Rick A Huse, 28

William Huse Phones & Addresses

  • Lees Summit, MO
  • Solana Beach, CA
  • Overland Park, KS
  • Rancho Santa Fe, CA
  • 1993 Zapo St, Del Mar, CA 92014
  • 530 Zuni Dr, Del Mar, CA 92014
  • La Jolla, CA
  • New York, NY
  • San Diego, CA

Work

Company: Advanced molecular design Sep 2007 Position: Ceo

Education

Degree: post doc School / High School: Cold Spring Harbor Laboratory 1982 to 1986 Specialities: Chemistry

Industries

Biotechnology

Resumes

Resumes

William Huse Photo 1

Ceo, Advanced Molecular Design

View page
Position:
CEO at Advanced Molecular Design
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Advanced Molecular Design since Sep 2007
CEO
Applied Molecular Evolution 1990 - 2007
President andCeo
The Scripps Research Institute 1989 - 1990
Consultant
Education:
Cold Spring Harbor Laboratory 1982 - 1986
post doc, Chemistry Albert Einstein College of Medicine of Yeshiva University 1975 - 1982
MD, PhD, Neuroscience Massachusetts Institute of Technology 1971 - 1975
BS, Chemistry

Business Records

Name / Title
Company / Classification
Phones & Addresses
William J. Huse
President
Kansas City Ob Gyn Pysicians PC
Medical Doctor's Office
10339 Alhambra St, Overland Park, KS 66207
William Huse
CEO
Applied Molecular Evolution
Surgeons · Commercial Physical Research · Research & Development in Biotechnology · Biotechnology Products & Servi
3520 Dunhill St, San Diego, CA 92121
(858) 597-4990, (858) 597-4950
William J. Huse
Medical Doctor, President
William J Huse II
Medical Doctor's Office
930 Carondelet Dr, Kansas City, MO 64114
William J. Huse
President
KANSAS CITY HEART GROUP, PC
Doctors' Office · Surgeons · Cardiologist · Internist · Vascular Surgery · Offices of Physicians, Except Mental Health
930 Carondelet, Kansas City, MO 64114
11409 Mnr Rd, Shawnee Mission, KS 66211
(816) 941-7727

Publications

Us Patents

Tumor Specific Internalizing Antigens And Methods For Targeting Therapeutic Agents

View page
US Patent:
6348194, Feb 19, 2002
Filed:
Nov 13, 1995
Appl. No.:
08/555684
Inventors:
William D. Huse - Del Mar CA
Jeffry D. Watkins - Encinitas CA
Assignee:
Ixsys Incorporated - San Diego CA
International Classification:
A61K 39395
US Classification:
4241431, 4242771, 4241551, 4241791, 4241831, 424 1, 4241381, 5303888, 5303897, 5303917, 514 25
Abstract:
The invention provides a method of reducing the proliferation of a neoplastic cell. The method consists of contacting the neoplastic cell with a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen. The neoplastic cell specific internalizing anitgen can be selected from the group consisting of lamp-2 and limp II families of lysosomal integral membrane proteins. Also provided is a method of intracellular targeting of a cytotoxic or cytostatic agent to a neoplastic cell population. The method consists of administering to an individual containing a neoplastic cell population a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen that is expressed by the neoplastic cell population, wherein the cytotoxic or cytostatic binding agent is bound by the neoplastic cell specific internalizing antigen and is internalized into the intracellular compartment. A method of reducing tumor growth through the intracellular targeting of a cytotoxic agent is also provided.

Tumor Specific Internalizing Antigens And Methods For Targeting Therapeutic Agents

View page
US Patent:
6420126, Jul 16, 2002
Filed:
Jun 8, 1999
Appl. No.:
09/328128
Inventors:
William D. Huse - Del Mar CA
Jeffry D. Watkins - Encinitas CA
Assignee:
Ixsys, Inc. - San Diego CA
International Classification:
G01N 33574
US Classification:
435 723, 435 71, 435 72, 435 721, 435 79, 4241741, 4241431, 4241791, 4241831, 4241521, 4241551, 514 25, 436501, 436538
Abstract:
The invention provides a method of reducing the proliferation of a neoplastic cell. The method consists of contacting the neoplastic cell with a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen. The neoplastic cell specific internalizing anitgen can be selected from the group consisting of lamp-2 and limp II families of lysosomal integral membrane proteins. Also provided is a method of intracellular targeting of a cytotoxic or cytostatic agent to a neoplastic cell population. The method consists of administering to an individual containing a neoplastic cell population a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen that is expressed by the neoplastic cell population, wherein the cytotoxic or cytostatic binding agent is bound by the neoplastic cell specific internalizing antigen and is internalized into the intracellular compartment. A method of reducing tumor growth through the intracellular targeting of a cytotoxic agent is also provided.

Anti-V3 Recombinant Human Antibodies And Nucleic Acids Encoding Same

View page
US Patent:
6531580, Mar 11, 2003
Filed:
Jun 24, 1999
Appl. No.:
09/339922
Inventors:
William D. Huse - Del Mar CA
Herren Wu - San Diego CA
Assignee:
Ixsys, Inc. - San Diego CA
International Classification:
C07K 1628
US Classification:
53038822, 5303871, 5303873, 5303881, 5303882, 536 231, 536 235, 536 2353
Abstract:
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to , or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of by contacting with an enhanced LM609 grafted antibody.

Anti-V3 Recombinant Human Antibodies, Nucleic Acids Encoding Same

View page
US Patent:
6590079, Jul 8, 2003
Filed:
Jan 30, 1997
Appl. No.:
08/791391
Inventors:
William D. Huse - Del Mar CA
Scott M. Glaser - Seattle WA
Assignee:
IXSYS, Incorporated - San Diego CA
International Classification:
C07K 1628
US Classification:
53038822, 5303871, 5303873, 5303881, 5303882, 536 2353, 4241301, 4241331, 4241411, 4241431, 4241521, 4241721
Abstract:
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided.

Anti-V33 Recombinant Human Antibodies, Nucleic Acids Encoding Same

View page
US Patent:
6596850, Jul 22, 2003
Filed:
Jan 30, 1998
Appl. No.:
09/016061
Inventors:
William D. Huse - Del Mar CA
Assignee:
Ixsys, Incorporated - San Diego CA
International Classification:
C07K 1628
US Classification:
5303873, 5303871, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875, 536 231, 536 234, 536 235, 536 2353, 4241301, 4241331, 4241411, 4241431, 4241441, 4241531, 4241541, 4241731
Abstract:
The invention provides a LM609 grafted antibody comprising one or more CDRs having at least one amino acid substitution, where the LM609 grafted antibody has binding activity. Nucleic acids encoding LM609 grafted heavy and light chains are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of. The method consists of contacting with a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to. Finally, the invention provides for a method of treating an -mediated disease. The method consists of administering an effective amount a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to.

Ultra High Affinity Neutralizing Antibodies

View page
US Patent:
6656467, Dec 2, 2003
Filed:
Jan 26, 2001
Appl. No.:
09/771415
Inventors:
James F. Young - Darnestown MD
Leslie S. Johnson - Germantown MD
William D. Huse - Del Mar CA
Herren Wu - Houston TX
Jeffry D. Watkins - Encinitis CA
Assignee:
MedImmune, Inc. - Gaithersburg MD
Applied Molecular Evolution - San Diego CA
International Classification:
A61K 3942
US Classification:
4241471, 4241331, 5303883
Abstract:
Ultra high affinity antibodies with binding affinities in the range of 10 M , and even 10 M are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.

Tumor Specific Human Monoclonal Antibodies And Methods Of Use

View page
US Patent:
6787638, Sep 7, 2004
Filed:
Dec 2, 1998
Appl. No.:
09/203768
Inventors:
Jeffry D. Watkins - Encinitas CA
William D. Huse - Del Mar CA
Assignee:
Applied Molecular Evolution, Inc. - San Diego CA
International Classification:
C07K 1600
US Classification:
53038885, 53038815, 5303917, 4241421
Abstract:
The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.

Methods Of Optimizing Antibody Variable Region Binding Affinity

View page
US Patent:
6849425, Feb 1, 2005
Filed:
Nov 4, 1999
Appl. No.:
09/434870
Inventors:
William D. Huse - Del Mar CA, US
Jeffry D. Watkins - Encinitas CA, US
Herren Wu - San Diego CA, US
Assignee:
Ixsys, Inc. - San Diego CA
International Classification:
C12N 1500
US Classification:
435 691, 435 696, 5303873
Abstract:
The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided.
Control profile
William D Huse from Lees Summit, MODeceased Get Report